We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
23 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Korsuva (difelikefalin) is approved to treat moderate-to-severe pruritus associated with chronic kidney disease in adults on haemodialysis.
-
Australian Public Assessment Report (AusPAR)Tavneos (avacopan), in combination with a rituximab- or cyclophosphamide-based regimen, has been approved for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis
-
Prescription medicine decision summaryTGA decision: Tavneos (avacopan) is approved to treat adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).
-
Prescription medicine registrationActive ingredients: ferric carboxymaltose.
-
-
Prescription medicine decision summaryKorsuva (difelikefalin acetate) is approved to treat chronic kidney disease
-
Prescription medicine registrationActive ingredients: difelikefalin acetate.
-
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Ferric carboxymaltose
-
Prescription medicine registrationActive ingredients: ferric carboxymaltose.